Open AccessReal-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
Author(s) -
Jenny Isaksson,
Henrik Gréen,
Dimitrios Papantoniou,
Linn Pettersson,
Mats Anden,
Johan Rosell,
Elisabeth ÅvallLundqvist,
Nils Elander
Publication year - 2021
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v12.i11.1009
Subject(s) - docetaxel , medicine , prostate cancer , clinical endpoint , oncology , androgen deprivation therapy , cohort , adverse effect , cancer , clinical trial
The majority of patients with newly diagnosed metastatic prostate cancer (PC) initially respond to androgen deprivation therapy (ADT) and are classified as metastatic castration-sensitive PC (mCSPC). Following months to years of ADT, the disease tends to become resistant to ADT. Recent randomized phase-III trials demonstrated a survival benefit with the addition of upfront docetaxel to ADT in mCSPC. Following its implementation in routine care, this combined treatment strategy requires more detailed evaluation in a real-world setting.